New hope for kidney cancer: drug combo after radiation shows promise in early trial
NCT ID NCT07223541
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two immunotherapy drugs, cemiplimab and fianlimab, given after targeted radiation for kidney cancer that has spread to a few spots in the body. The goal is to see if adding fianlimab helps control the cancer longer than cemiplimab alone. About 72 adults with clear cell renal cell carcinoma and up to 5 metastatic lesions will participate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Oklahoma Health Sciences Center
RECRUITINGOklahoma City, Oklahoma, 73104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple strike of radiation, targeted therapy, and immunotherapy tame metastatic kidney cancer?
- Can a Two-Pronged immune attack shrink kidney tumors before surgery?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Drug cocktail aims to shrink kidney tumors before surgery and prevent return
- Smart bomb for kidney cancer: imaging and radiation combo targets tough tumors